##Sauer H, Oertel WH. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. J Neurosci. 59:401-15.##Tadibi V, Yosefi B, Taheri H, Taherzadeh J. 2008. Following a period of motor function in patients with Parkinson's Movement Therapy. journal of pajohesh. 18:157-169.[persian].##Schwarting RK, Huston JP. 1997. Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology. 18: 689-708. ##Dauer W, Przedborski S. 2003. Parkinson’s disease: Mechanisms and models. Neuron. 39:889-909.##Olanow CW
. 1990. Oxidation reactions in Parkinson's disease. Neurology.
40: 32-37.## Gerlach
P. 1996. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. Journal of Neural Transmission
. 103:987-1041.##Sautter J, Kupsch A, earl CD, Oertel WH. 1997. degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat:behavioral and biochemical changes and pretreatment with the calcium-entry blocker nimodipine. Exp Brain Res. 117:111-119.##Lotharius J, Dugan LL, OMalley KL. 1999. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J neuroscience. 19(4):1284-93.##Hellman M, Peranen J, Saarma M, Permi P. 2010. 1H, 13C and 15N resonance assignments of the human mesencephalic astrocyte-derived neurotrophic factor. Biomol NMR Assign. 4:215–217.##Lindholm P, Saarma M. 2010. Novel CDNF/MANF family of neurotrophic factors. DevNeurobiol. 70(5):360-71.##
Lindholm P. 2007. Novel CDNF/MANF protein family: molecular structure, expression and neurotrophic activity. University of Helsinki. 1:45-46.##Sun ZP, Gong L, Huang SH, Geng Z, Cheng L, Chen ZY. 2011. Intracellular trafficking and secretion of cerebral dopamine neurotrophic factor in neurosecretory cells. Journal of Neurochimistry. 117:121–132.##Wilmore JH, Costill DL, Larry KW, translated by: Moeeni Z, Rahmaninia F, Rajabi H, Aghaalinejad H, Salami F. 1389. Physiology of sport and exercise. Book. Published by Mobtakeran.##Paul J, Kuruvilla KP, Mathew J, Kumar P, Paulose CS. 2011. Dopamine D 1 and D 2 receptor subtypesfunctional regulation in cerebral cortex of unilateral rotenon e lesione d Parkinson’s rat model: Effect of serotonin, dopamine and norepinephrine. Parkinsonism and Related Disorders. 17:255- 259.##Sterm MB. 2005. Parkinson disease. Early Diagnosis and management JfamPrace. 36(4):439-46.##Wu SY
, Wang TF, Yu L, Jen CJ, Chuang JI, Wu FS, et al. .2011. Running exercise protects the substantianigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway. 25(1):135-46.##Hyman C
, Hofer M
, Barde YA
, Juhasz M
, Yancopoulos GD
, Squinto SP
. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantianigra. LindsayRM.Regeneron Pharmaceuticals Inc. Tarrytown, New York. 10591-6707.##Radak Z, Kumagai Sh, Taylor AW, Naito H, Goto S. 2007. Effects of exercise on brain function: role of freeradicals. ApplPhysiolNutrMetab. 32(5): 942-946.##Ji LL. 1993. Antioxidant enzyme response to exercise and aging Med Sci Sports Exerc. 25(2):225–31.##Rodríguez M, Abdala P, Barroso-Chinea P, Obeso J, González-Hernández T. 2001. Motor behaviorar change after intracerebrovenricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson’s disease. Behav Brain Res. 122(1):79-92.##Shachar D, Kahana N, Kampel V, Warshawsky A, Youdim M. 2004. Neuroprotection by novel brain permeable iron chelator, VK-28 against 6-hydroxydopamine lesion in rats. Neuropharmacology. 46(2):254-63.##Hubrecht R, Kirkwood J. 2010. The Care and Management of Laboratory and Other Research Animals. A John Wiley & Sons, Ltd. Publication. 540. ##Voutilainen Merja H. 2010. CDNF and MANF in an experimental model of Parkinson’s disease in rats. Academic dissertation university of Helsinki. ## Sachs C, Jonsson G. 1975. Mechanism of action of 6-hydroxydopmine. Biochem Pharmocol. 24:1-8.##Schober A. 2004. Classic toxin-induced animal models of Parkinsons diseas : 6-OHDA and MPTP. Cell Tissue Res. 318:215-334.##Kim R, Emi M, Tanabe K, Murakami S. 2006. Role of the unfolded protein response in cell death. Apoptosis. 11:5-13.##Maguire Zeiss K, Short DW, Federoff HJ. 2005. Synuclein ,dopamine and oxidative stress:co-conspirator in Parkinson desease. Brain ResMol. 134:18-23.##Toth G, Yang H, Anguelov RA, Vettraino J, Wang Y, Acsadi G. 2002. Gene transfer of glial cell-derived neurotrophic factor and cardiotrophin-1 protect PC12 cells from injury:involvement of the phosphatidylinositol 3-Kinase and mitogen-activated protein kinase kinase pathways. J.Neurosci.Res. 69:622-632.##Smith MP, Cass WA. 2007. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinsons disease. Neurosci.Lett. 412:259-263.# Zoladz JA, Pilc A, Majerczak J, Grandys M, Zapart-Bukowska J, Duda K. 2008. Endurance training increases plasma brain-derived neurotrophic factor concentration in young healthy men.
J Physiol Pharmacol. 7:119-32.##Hajizade Moghadam A, Fallah Mohammadi Z, Sheykh P, Mirzaee S. 1391. Effect of voluntary exercise on a running wheel and brain-derived neurotrophic factor levels Paradvksvm Allium extracts in alloxan-induced diabetic rat hippocampus. Iranian Journal of Diabetes and Lipid Disorders. 4:350.[Persian].##